Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 18;19(10):1728-1737.
doi: 10.2174/1570159X19666210113151136.

The Benzydamine Experience: A Systematic Review of Benzydamine Abuse

Stefania Chiappini  1 , Andrea Miuli  2 , Alessio Mosca  2 , Mauro Pettorruso  2 , Amira Guirguis  3 , Martin Corkery John  1 , Giovanni Martinotti  2 , Massimo Di Giannantonio  2 , Fabrizio Schifano  1
Affiliations

The Benzydamine Experience: A Systematic Review of Benzydamine Abuse

Stefania Chiappini et al. Curr Neuropharmacol. .

Abstract

Background: Both prescription and over-the-counter (OTC) drugs recently emerged among novel psychoactive substances (NPS) being reported as ingested for recreational purposes. Among them, benzydamine (BZY), normally prescribed as an OTC anti-inflammatory drug, is reportedly being diverted and recreationally used.

Objective: The aim of this study was to investigate how the misuse of BZY has been reported, illustrating its psychotropic molecular mechanism, and studying its psychopathological effects.

Methods: We firstly conducted a systematic review of the literature concerning the abuse of BZY and its effects. For data gathering purposes, both PRISMA and PROSPERO guidelines were followed. All research methods were approved by PROSPERO (identification code CRD42020187266). Second, we analysed BZY-related data from the European Monitoring Agency (EMA) Adverse Drug Reactions (ADRs) database recorded during 2005-2020 regarding its abuse.

Results: Eleven articles, published during 1997-2019, were included in our systematic review, including five case reports, four surveys, and two retrospective case series analyses. While nine articles dealt with the recreational use of BZY, two described an oral overdose of the drug. When specified, dosages of BZY consumed ranged from 500 to 1500mg. The EMA dataset contained three cases of BZY abuse.

Conclusion: Results from the systematic review showed BZY might be diverted for typical hallucinogenic properties occurring at high dosages. Healthcare professionals should be warned about a possible misuse/abuse of a commonly prescribed anti-inflammatory drug and be vigilant when prescribing it. Physicians working in emergency units should know that psychotic symptoms may be related to BZY abuse.

Keywords: Benzydamine; NPS; benzydamine misuse; novel psychoactive substances.; over-the-counter drug abuse.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
PRISMA flow-diagram regarding the retrieved studies on Benzydamine abuse/misuse.
Fig. (2)
Fig. (2)
Risk of bias.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. National Center for Biotechnology Information. PubChem Compound Summary for CID 12555, Benzydamine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Benzydamine (Accessed Dec 12, 2020).
    1. Avvisati R., Meringolo M., Stendardo E., Malavasi E., Marinelli S., Badiani A. Intravenous self-administration of benzydamine, a non-steroidal anti-inflammatory drug with a central cannabinoidergic mechanism of action. Addict. Biol. 2018;23(2):610–619. doi: 10.1111/adb.12516. - DOI - PubMed
    1. Quane P.A., Graham G.G., Ziegler J.B. Pharmacology of benzydamine. Inflammopharmacology. 1998;6(2):95–107. doi: 10.1007/s10787-998-0026-0. - DOI - PubMed
    1. Gómez-López L., Hernández-Rodríguez J., Pou J., Nogué S. Acute overdose due to benzydamine. Hum. Exp. Toxicol. 1999;18(7):471–473. doi: 10.1191/096032799678840264. - DOI - PubMed
    1. Baldock G.A., Brodie R.R., Chasseaud L.F., Taylor T., Walmsley L.M., Catanese B. Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects. Biopharm. Drug Dispos. 1991;12(7):481–492. doi: 10.1002/bdd.2510120702. - DOI - PubMed

Publication types